Kidney Cancer Journal 59
immunotherapy products for cancer, has enrolled the first
patient in Part 2 of JX594-REN026, a Phase 1b clinical trial of
Pexa-Vec (pexastimogene devacirepvec) in combination
with Libtayo®(cemiplimab-rwlc), for the treatment of RCC.
Enrollment of Part 1 (dose-escalation phase) of the trial was
completed in March 2019 without significant safety concerns,
and the first seven patients in Part 2 were enrolled in
South Korea, with expansion to sites in the United States
and Australia anticipated.
SillaJen is collaborating with Regeneron to evaluate
Pexa-Vec, SillaJen’s lead clinical candidate, in combination
with Regeneron’s Libtayo®, an anti-PD1 monoclonal antibody
Regeneron is developing in collaboration with Sanofi.
The aim of the trial is to assess the safety and efficacy of the
combination in patients with unresectable or metastatic
renal cell carcinoma. The study will also investigate the immune
modulating potential of Pexa-Vec given concurrently
with checkpoint inhibitor therapy by evaluating multiple
blood and tissue biomarkers. KCJ
• Treatment Beyond Progression in
RCC Patients Treated with IO
Approaches
• Revisiting the Role of Nephrectomy
in Metastatic RCC
• The Role of Precision Medicine and
Next Generation Sequencing in ccRCC
A click away.
To explore these and other topics in the
Kidney Cancer Journal, visit the journal
website: kidney-cancer-journal.com.
/kidney-cancer-journal.com